Deal watch: BMS bets on biologic immunotherapies.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use*; D001709:Biotechnology; D019496:Cancer Vaccines; D004345:Drug Industry; D006801:Humans; D007167:Immunotherapy / Q000191:economics / Q000639:trends*
D000911:Antibodies, Monoclonal; D001688:Biological Products; D019496:Cancer Vaccines